TLD-1433 against additional bladder indicationsTLD-1433 is for the moment only adressing the BCG-Unresponsive for CIS. But they could also address another one in the bladder indication, not to mention MIBC. BioImmune is already targetting 2 bladder sub-indications (see below).
That's why a big pharma could want to jv and expand, within the bladder indication and other cancer indications. That's why they could be interested in our oncology platform (ACT) as it would offer more options.
So we can go by indications or for the whole package. It will depend on how attractive we are seen.
Anktiva has been awarded both Breakthrough Therapy and Fast Track designations by the FDA for the treatment of BCG-unresponsive NMIBC CIS, as well as Fast Track designation for BCG-unresponsive NMIBC papillary and BCG-nave NMIBC CIS.
Bladder Cancer:
BCG Unresponsive NMIBC Carcinoma In-Situ (CIS) & Papillary
Bladder Cancer:
BCG Nave NMIBC CIS & Papillary